The panel also acknowl- edged that the evidence supported BP control, rather than a specific agent used to achieve that control, as the most relevant consideration for their recommendation.7 Supporting this, historically, most antihypertensive drugs have demonstrated comparable cardiovascular efficacy Specifically, diuretic-based antihyperten- sive therapies have been shown to prevent HF in a wide range of target populations as first-line therapy.27,35 39 Additionally, low-dose diuretics have been shown to be more effective as a first-line treatment for preventing the development of HF compared with ACE inhibitors, -blockers, or calcium channel blockers by meta-analy- It should also be noted that most of the original tri- als used the longer-acting chlorthalidone rather than hy- drochlorothiazide. ACE inhibitors have also been shown to be very effective in the prevention of HF,14,27,35,40 even more significantly in patients with left ventricular (LV) sys- tolic dysfunction or patients after MI.41,42 Likewise, ARBs have been shown to reduce the incidence of HF, espe- cially in patients with hypertension and type 2 diabetes mellitus and nephropathy.43,44 However, calcium channel blockers appear to be somewhat less efficacious than the above agents for preventing HF.8,27 There are inad- equate data to determine whether this is true only for dihydropyridine calcium channel blockers or whether it is true of the entire class of drugs.26 Regarding -blockers, in the ALLHAT trial (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial), doxazosin was inferior to chlorthalidone for the prevention of HF and was associated with the doubling of HF risk compared The 2013 ACCF/AHA Guideline for the Management of Heart Failure indicated that the role of calcium antagonists or -blockers is less clear for reducing the risk for incident HF, and the choice of antihypertensive therapy should follow the contempo- In addition to medications, patients with hypertension should be advised on healthy lifestyle modi- fication; weight reduction; reduction of sodium intake; increased consumption of fruits, vegetables, and low-fat dairy products; and moderation of alcohol intake.7,9,14 In patients with stage B HF with structural heart disease or LV dysfunction but without HF symptoms, there is benefit with ACE inhibitors, ARBs, or -blockers (Table 3). 